|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-7-6
|
|
pubmed:abstractText |
To compare the safety and efficacy of amprenavir [APV/j Agenerase trade mark; GlaxoSmithKline, [Ware, UK; 600 mg twice a day (bid)] boosted with low-dose ritonavir (RTV, 100 mg bid) with those of other protease inhibitors (PIs) in PI-experienced HIV-infected patients. Study
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1464-2662
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
296-302
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15236620-Adolescent,
pubmed-meshheading:15236620-Adult,
pubmed-meshheading:15236620-Aged,
pubmed-meshheading:15236620-Anti-HIV Agents,
pubmed-meshheading:15236620-Carbamates,
pubmed-meshheading:15236620-Female,
pubmed-meshheading:15236620-Genes, Viral,
pubmed-meshheading:15236620-HIV Infections,
pubmed-meshheading:15236620-HIV Protease Inhibitors,
pubmed-meshheading:15236620-HIV-1,
pubmed-meshheading:15236620-Humans,
pubmed-meshheading:15236620-Male,
pubmed-meshheading:15236620-Middle Aged,
pubmed-meshheading:15236620-Ritonavir,
pubmed-meshheading:15236620-Sulfonamides
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.
|
|
pubmed:affiliation |
Hospital Doce de Octubre, Madrid, Spain. fpulido@nacom.es
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
